Octreotide LAR: Safety and tolerability issues

Expert Opinion on Drug Safety

Volumn 8, Issue 6, 2009, Pages 755-768

  Bornschein, Jan ^a   Drozdov, Ignat ^b   Malfertheiner, Peter ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acromegaly; Carcinoid syndrome; Growth hormone; IGF 1; Lanreotide; Neuroendocrine tumors; Octreotide; Somatostatin analogues

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; OCTREOTIDE;

ACROMEGALY; ADULT; AGE; ANIMAL; DELAYED RELEASE FORMULATION; FEMALE; HUMAN; NEUROENDOCRINE TUMOR; POSTMARKETING SURVEILLANCE; PREGNANCY; REVIEW;

ACROMEGALY; ADULT; AGE FACTORS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; NEUROENDOCRINE TUMORS; OCTREOTIDE; PREGNANCY; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 77449098783     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740330903379525     Document Type: Article

References (130)

1. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:77-9 • Key paper on the discovery of somatostatin.
2. Lancranjan I, Bruns C, Grass P, et al. Sandostatin LAR: pharmacokinetics, pharmocodynamics, efficacy, and tolerability in acromegalic patients. Metabolism 1995;44:18-26 •• Key paper on pharmacokinetics and pharmacodynamics of octreotide LAR.
3. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Intern Med 1991;151:1573-8 • One of the first multi-center long-term studies on subcutaneous octreotide in the treatment of acromegaly.
4. Sassolas G. The role of sandostatin in acromegaly. Metabolism 1992;41:39-43
5. Ezzat S, Snyder PJ, Young WF, et al. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med 1992;117:711-18
6. Christensen SE, Weeke J, Orskov H, et al. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients. Clin Endocrinol (Oxf) 1987;27:297-306 (Pubitemid 17138333)
7. Tauber JP, Babin T, Tauber MT, et al. Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly. J Clin Endocrinol Metab 1989;68:917-24 (Pubitemid 19127410)
8. Roelfsema F, Frolich M, Harris AG. Octreotide treatment in acromegaly: a comparison between pen-treated and pump-treated patients in a cross-over study. Acta Endocrinol (Copenh) 1991;125:43-8
9. Bevan JS. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005;90:1856-63 • Comprehensive Review on antitumoral effects of SSA in acromegaly. (Pubitemid 40464061)
10. Garcia de la TN, Wass JA, Turner HE. Antiangiogenic effects of somatostatin analogues. Clin Endocrinol (Oxf) 2002;57:425-41
11. Plockinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004;80:394-424 •• Consensus guidelines on the treatment of NETs in Europe (ENETS). (Pubitemid 40874886)
12. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001;12(Suppl 2):S111-14 • Review and recommendation for therapy of NETs. (Pubitemid 33069698)
13. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006;17:1733-42 • Review on the antitumoral effects of SSA. (Pubitemid 44884046)
14. Reubi JC, Zimmermann A, Jonas S, et al. Regulatory peptide receptors in human hepatocellular carcinomas. Gut 1999;45:766-774 (Pubitemid 29492155)
15. Becker G, Allgaier HP, Olschewski M, et al. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 2007;45:9-15 (Pubitemid 46144359)
16. Cebon J, Findlay M, Hargreaves C, et al. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer 2006;95:853-61 (Pubitemid 44498101)
17. Yuen MF, Poon RT, Lai CL, et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002;36:687-91 (Pubitemid 34977180)
18. Reubi JC. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 2004;80(Suppl 1):51-6 •v Landmark paper on the expression pattern of sst-receptors.
19. Koizumi M, Onda M, Tanaka N, et al. Antiangiogenic effect of octreotide inhibits the growth of human rectal neuroendocrine carcinoma. Digestion 2002;65:200-6
20. Cascinu S, Del Ferro E, Ligi M, et al. Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients. Cancer Invest 2001;19:8-12 (Pubitemid 32233796)
21. Vidal S, Kovacs K, Horvath E, et al. Microvessel density in pituitary adenomas and carcinomas. Virchows Arch 2001;438:595-602 (Pubitemid 32662379)
22. Grant MB, Caballero S, Millard WJ. Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization. Regul Pept 1993;48:267-78
23. Bhathena SJ, Louie J, Schechter GP, et al. Identification of human mononuclear leukocytes bearing receptors for somatostatin and glucagon. Diabetes 1981;30:127-31 (Pubitemid 11018680)
24. Elliott DE, Li J, Blum AM, et al. SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release. Eur J Immunol 1999;29:2454-63 (Pubitemid 29378115)
25. Dalm VA, Hofland LJ, Ferone D, et al. The role of somatostatin and somatostatin analogs in the pathophysiology of the human immune system. J Endocrinol Invest 2003;26:94-102
26. de Franchis R. Somatostatin, somatostatin analogues and other vasoactive drugs in the treatment of bleeding oesophageal varices. Dig Liver Dis 2004;36(Suppl 1):S93-100
27. Corley DA, Cello JP, Adkisson W, et al. Octreotide for acute esophageal variceal bleeding: a meta-analysis. Gastroenterology 2001;120:946-54 (Pubitemid 32193191)
28. Connor S, Alexakis N, Garden OJ, et al. Meta-analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgery. Br J Surg 2005;92:1059-67 (Pubitemid 41284869)
29. Zeng Q, Zhang Q, Han S, et al. Efficacy of somatostatin and its analogues in prevention of postoperative complications after pancreaticoduodenectomy: a meta-analysis of randomized controlled trials. Pancreas 2008;36:18-25
30. Rosenoff SH, Gabrail NY, Conklin R, et al. A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial. J Support Oncol 2006;4:289-94 (Pubitemid 44203632)
31. Nicholls J, Wynick D, Domin J, et al. Pharmacokinetics of the long-acting somatostatin analogue octreotide (SMS 201-995) in acromegaly. Clin Endocrinol (Oxf) 1990;32:545-50 (Pubitemid 20151449)
32. Chanson P, Timsit J, Harris AG. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clin Pharmacokinet 1993;25:375-91 (Pubitemid 23327923)
33. Kutz K, Nuesch E, Rosenthaler J. Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol Suppl 1986;119:65-72 (Pubitemid 16057845)
34. Lamberts SW. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev 1988;9:417-36 •• Key reference for the use of octreotide in pituitary tumors.
35. Grass P, Marbach P, Bruns C, et al. Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships. Metabolism 1996;45:27-30
36. Chen T, Miller TF, Prasad P, et al. Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. J Clin Pharmacol 2000;40:475-81 • Key reference for pharmacodynamics and pharmacokinetics of octreotide LAR.
37. Zhou H, Chen TL, Marino M, et al. Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects. Br J Clin Pharmacol 2000;50:543-52 (Pubitemid 32010015)
38. Lancranjan I, Bruns C, Grass P, et al. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism 1996;45:67-71
39. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003;24:28-47 • Key reference on receptor affinity of different SSA. (Pubitemid 36223278)
40. Bertherat J, Chanson P, Dewailly D, et al. Resistance to somatostatin (SRIH) analog therapy in acromegaly. Re-evaluation of the correlation between the SRIH receptor status of the pituitary tumor and the in vivo inhibition of GH secretion in response to SRIH analog. Horm Res 1992;38:94-9 (Pubitemid 23163261)
41. Reubi JC, Landolt AM. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab 1989;68:844-50 • Key reference on SSA reponse and receptor status. (Pubitemid 19089019)
42. Ikuyama S, Nawata H, Kato K, et al. Specific somatostatin receptors on human pituitary adenoma cell membranes. J Clin Endocrinol Metab 1985;61:666-71 (Pubitemid 16248088)
43. Ikuyama S, Nawata H, Kato K, et al. Plasma growth hormone responses to somatostatin (SRIH) and SRIH receptors in pituitary adenomas in acromegalic patients. J Clin Endocrinol Metab 1986;62:729-33 (Pubitemid 16138146)
44. Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci 2008;1;13:822-840 •• Comprehensive review on molecular mechanisms involved in somatostatin signaling.
45. Halperin I, Nicolau J, Casamitjana R, et al. A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients. Horm Metab Res 2008;40:422-6 (Pubitemid 351967135)
46. Freda PU, Katznelson L, van der Lely AJ, et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005;90:4465-73 • Meta-analysis on long-acting SSA in acromegaly. (Pubitemid 41159328)
47. Flogstad AK, Halse J, Haldorsen T, et al. Sandostatin LAR in acromegalic patients: a dose-range study. J Clin Endocrinol Metab 1995;80:3601-7
48. Auriemma RS, Pivonello R, Galdiero M, et al. Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: a retrospective, comparative, head-to-head study. J Endocrinol Invest 2008;31:956-65
49. Colao A, Auriemma RS, Galdiero M, et al. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-i levels, tumor shrinkage, and cardiovascular disease: a Prospective Study. J Clin Endocrinol Metab 2009. [Epub ahead of print] • Key reference for outcome of long-term treatment with octreotide LAR in acromegaly.
50. Stewart PM, Stewart SE, Clark PM, et al. Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR). Clin Endocrinol (Oxf) 1999;50:295-9 (Pubitemid 29166707)
51. Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 2003;88:3090-8 (Pubitemid 36877477)
52. Giustina A, Bonadonna S, Bugari G, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 2009;161:331-8
53. Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006;91:1397-403 • First published key reference for first-line long-term treatment of acromegaly with octreotide LAR.
54. Jenkins PJ, Akker S, Chew SL, et al. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clin Endocrinol (Oxf) 2000;53:719-24 (Pubitemid 32096683)
55. Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002;87:4554-63 • Key reference for octreotide as primary treatment in acromegaly.
56. Mercado M, Borges F, Bouterfa H, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 2007;66:859-68 (Pubitemid 47024274)
57. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999;17:600-6 (Pubitemid 29075248)
58. Kolby L, Wangberg B, Ahlman H, et al. Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors. World J Surg 1998;22:679-83 (Pubitemid 28277861)
59. Ronchi CL, Varca V, Beck-Peccoz P, et al. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 2006;91:121-8 • Key reference for long-term results of octreotide LAR treatment versus surgery with respect to cardiovascular risk. (Pubitemid 43069127)
60. Manelli F, Desenzani P, Boni E, et al. Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy. Pituitary 1999;2:205-10
61. Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 1997;53:681-99 (Pubitemid 27145959)
62. Colao A, Pivonello R, Rosato F, et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf) 2006;64:342-51
63. Colao A, Cappabianca P, Caron P, et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin Endocrinol (Oxf) 2009;70:757-68 • Key reference for comparison of efficacy of octreotide LAR versus surgery as first-line treatment in acromegaly.
64. Colao A, Pivonello R, Auriemma RS, et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006;91:2112-18 (Pubitemid 43854991)
65. Carlsen SM, Lund-Johansen M, Schreiner T, et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 2008;93:2984-90
66. Colao A, Attanasio R, Pivonello R, et al. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2006;91:85-92 • Key reference on combination of SSA with neurosurgery. (Pubitemid 43069122)
67. Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 2008;159:89-95 •• Landmark meta-analysis on the effect of SSA on serum levels of GH and IHGF-1 in acromegaly.
68. Buchanan KD. Effects of sandostatin on neuroendocrine tumours of the gastrointestinal system. Recent Results Cancer Res 1993;129:45-55
69. Creutzfeldt W. Carcinoid tumors: development of our knowledge. World J Surg 1996;20:126-31 (Pubitemid 26069476)
70. Tomassetti P, Migliori M, Corinaldesi R, et al. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther 2000;14:557-60 (Pubitemid 30240747)
71. Eriksson B, Janson ET, Bax ND, et al. The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours. Digestion 1996;57(Suppl 1):77-80 (Pubitemid 26183928)
72. Modlin IM, Latich I, Kidd M, et al. Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol 2006;4:526-47 •• Comprehensive review on therapeutic options for NETs.
73. Imam H, Eriksson B, Lukinius A, et al. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol 1997;36:607-14 (Pubitemid 27512573)
74. Butturini G, Bettini R, Missiaglia E, et al. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer 2006;13:1213-21 (Pubitemid 46212575)
75. Panzuto F, Di Fonzo M, Iannicelli E, et al. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol 2006;17:461-6 • Key paper on long-term outcome under SSA treatment for pancreatic cancer. (Pubitemid 43329584)
76. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide lar in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a Report From the PROMID Study Group. J Clin Oncol 2009. [Epub ahead of print] •• Landmark trial on the antitumoral efficacy of octreotide LAR in NETs.
77. Grozinsky-Glasberg S, Shimon I, Korbonits M, et al. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer 2008;15:701-20 •• Comprehensive review on the use of SSA in the treatment of NETs, including molecular pathways and clinical data.
78. Kidd M, Drozdov I, Joseph R, et al. Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer 2008;113:690-700
79. Nakashima M, Takano K, Matsuno A. Analyses of factors influencing the acute effect of octreotide in growth hormone-secreting adenomas. Endocr J 2009;56:295-304
80. Fougner SL, Borota OC, Berg JP, et al. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin Endocrinol (Oxf) 2008;68:458-65 (Pubitemid 351257867)
81. Turner HE, Thornton-Jones VA, Wass JA. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin Endocrinol (Oxf) 2004;61:224-31 (Pubitemid 39093118)
82. Treiber G, Rocken C, Wex T, et al. Octreotide alone or in combination with rofecoxib as palliative treatment for advanced hepatocellular cancer. Z Gastroenterol 2007;45:369-77 (Pubitemid 47055633)
83. Ganda OP, Weir GC, Soeldner JS, et al. "Somatostatinoma": a somatostatin-containing tumor of the endocrine pancreas. N Engl J Med 1977;296:963-7 • One of two papers on the discovery of somatostatinoma. (Pubitemid 8092492)
84. Larsson LI, Hirsch MA, Holst JJ, et al. Pancreatic somatostatinoma. Clinical features and physiological implications. Lancet 1977;1:666-8 • One of two papers on the discovery of somatostatinoma. (Pubitemid 8121565)
85. Krejs GJ, Orci L, Conlon JM, et al. Somatostatinoma syndrome. Biochemical, morphologic and clinical features. N Engl J Med 1979;301:285-92 (Pubitemid 9244490)
86. Ronchi C, Epaminonda P, Cappiello V, et al. Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Invest 2002;25:502-7 (Pubitemid 34661837)
87. Colao A, Marzullo P, Ferone D, et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 2000;85:3132-40 • Key reference for cardiovascular effects of SSA treatment in acromegaly.
88. Colao A, Pivonello R, Galderisi M, et al. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab 2008;93:2639-46 (Pubitemid 352008531)
89. Maison P, Tropeano AI, quin-Mavier I, et al. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2007;92:1743-7 •• Mete-analysis on the effect of SSA treatment on cardiovascular factors in acromegaly. (Pubitemid 46997181)
90. Clemmons DR, Underwood LE, Ridgway EC, et al. Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status. Am J Med 1980;69:571-5 (Pubitemid 10018713)
91. Helle SI, Omsjo IH, Hughes SC, et al. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. Clin Endocrinol (Oxf) 1996;45:727-32 (Pubitemid 27032319)
92. Kouroumalis E, Samonakis D, Skordilis P. Octreotide treatment of hepatocellular carcinoma. Hepatology 2003;37:477
93. Lancranjan I, Atkinson AB. Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group. Pituitary 1999;1:105-14 • Landmark trial on the treatment of pituitary adenomas with octreotide LAR.
94. Davies PH, Stewart SE, Lancranjan L, et al. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf) 1998;48:311-16 (Pubitemid 28137643)
95. Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients-a clinical research center study. J Clin Endocrinol Metab 1995;80:2768-75 • Pioneer study on the efficacy and safety of octreotide in acromegaly.
96. Moschetta A, Stolk MF, Rehfeld JF, et al. Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR. Aliment Pharmacol Ther 2001;15:181-5 (Pubitemid 32142494)
97. Redfern JS, Fortuner WJ. Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management. Am J Gastroenterol 1995;90:1042-52
98. Astruc B, Marbach P, Bouterfa H, et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol 2005;45:836-44 • Key reference for the different pharmacological characteristics of lanreotide and octreotide. (Pubitemid 40875336)
99. Plockinger U, Dienemann D, Quabbe HJ. Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly. J Clin Endocrinol Metab 1990;71:1658-62 (Pubitemid 120032790)
100. Baldelli R, Battista C, Leonetti F, et al. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf) 2003;59:492-9 (Pubitemid 37188181)
101. Colao A, Auriemma RS, Galdiero M, et al. Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. J Clin Endocrinol Metab 2009;94:528-37 • Key reference for long-term effects of octreotide LAR on glucose metabolism in acromegaly.
102. Mazziotti G, Floriani I, Bonadonna S, et al. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 2009;94:1500-8 •• Meta-analysis on the effect of long-term SSA treatment on glucose homeostasis.
103. Caron P, Gerbeau C, Pradayrol L. Maternal-fetal transfer of octreotide. N Engl J Med 1995;333:601-2
104. Fassnacht M, Capeller B, Arlt W, et al. Octreotide LAR treatment throughout pregnancy in an acromegalic woman. Clin Endocrinol (Oxf) 2001;55:411-15 • Key reference and overview on the literature concerning the use of octreotide LAR during pregnancy. (Pubitemid 32823052)
105. Caron P, Buscail L, Beckers A, et al. Expression of somatostatin receptor SST4 in human placenta and absence of octreotide effect on human placental growth hormone concentration during pregnancy. J Clin Endocrinol Metab 1997;82:3771-6 (Pubitemid 27509370)
106. Caron P, Gerbeau C, Pradayrol L, et al. Successful pregnancy in an infertile woman with a thyrotropin-secreting macroadenoma treated with somatostatin analog (octreotide). J Clin Endocrinol Metab 1996;81:1164-8 (Pubitemid 26083988)
107. Herman-Bonert V, Seliverstov M, Melmed S. Pregnancy in acromegaly: successful therapeutic outcome. J Clin Endocrinol Metab 1998;83:727-31 (Pubitemid 28496436)
108. Montini M, Pagani G, Gianola D, et al. Acromegaly and primary amenorrhea: ovulation and pregnancy induced by SMS 201-995 and bromocriptine. J Endocrinol Invest 1990;13:193 (Pubitemid 20111837)
109. Mozas J, Ocon E, Lopez de la TM, et al. Successful pregnancy in a woman with acromegaly treated with somatostatin analog (octreotide) prior to surgical resection. Int J Gynaecol Obstet 1999;65:71-3
110. Landolt AM, Schmid J, Wimpfheimer C, et al. Successful pregnancy in a previously infertile woman treated with SMS-201-995 for acromegaly. N Engl J Med 1989;320:671-2 (Pubitemid 19072480)
111. Mikhail N. Octreotide treatment of acromegaly during pregnancy. Mayo Clin Proc 2002;77:297-8 • Key reference and overview on the literature concerning the use of octreotide LAR during pregnancy.
112. Colao A, Pivonello R, Cappabianca P, et al. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. Clin Endocrinol (Oxf) 2005;63:342-9 (Pubitemid 41233454)
113. van der Lely AJ, Harris AG, Lamberts SW. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clin Endocrinol (Oxf) 1992;37:181-5
114. Gullichsen R. Long-acting octreotide in the treatment of diarrhea after pelvic pouch surgery. Tech Coloproctol 2006;10:346-9 (Pubitemid 46142595)
115. Attanasio R, Baldelli R, Pivonello R, et al. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab 2003;88:5258-65 • Key reference for the use of lanreotide in acromegaly. (Pubitemid 37452725)
116. Amato G, Mazziotti G, Rotondi M, et al. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 2002;56:65-71 • Key reference for effect of octrotide on tumorshrinkage in pituitary adenomas. (Pubitemid 34107323)
117. Ashwell SG, Bevan JS, Edwards OM, et al. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol 2004;150:473-80 (Pubitemid 38584697)
118. Ricci S, Antonuzzo A, Galli L, et al. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol 2000;11:1127-30
119. Andries M, Glintborg D, Kvistborg A, et al. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol (Oxf) 2008;68:473-80 (Pubitemid 351257869)
120. Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 2008;93:2957-68 •• Comprehensive comparison of different SSA for the treatment of acromegaly.
121. Murray RD, Kim K, Ren SG, et al. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab 2004;89:3027-32 (Pubitemid 38766404)
122. Hofland LJ, van der Hoek J, Feelders R, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005;152:645-54 (Pubitemid 40575811)
123. Pasquali D, Rossi V, Conzo G, et al. Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells. J Mol Endocrinol 2008;40:263-71 (Pubitemid 351865034)
124. Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 2008;286(1-2):69-74 (Pubitemid 351680237)
125. van der Hoek J, de Herder WW, Feelders RA, et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004;89:638-45 (Pubitemid 38269871)
126. Ma P, Wang Y, van der Hoek, et al. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clin Pharmacol Ther 2005;78:69-80 • Key study comparing octreotide with SOM230 (pasireotide).
127. Hofland LJ, van der Hoek J, Feelders R, et al. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. J Endocrinol Invest 2005;28:36-42
128. van der Hoek J, van der Lelij AJ, Feelders RA, et al. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. Clin Endocrinol (Oxf) 2005;63:176-84 (Pubitemid 41097986)
129. Kopchick JJ, Parkinson C, Stevens EC, et al. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 2002;23:623-46 (Pubitemid 35191626)
130. Colao A, Pivonello R, Auriemma RS, et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 2006;154:467-77 • Pioneer study of pegvisomat in patients refractory to SSA.